July 23, 2010 ·
Leave a comment
Press Release Out Today from the Offices of Thought Leader Select
July 22, 2010 (CHAPEL HILL, NC)—Thought Leader Select, a North Carolina company dedicated to delivering sophisticated key opinion leader research solutions to the biopharmaceutical industry, announces new key opinion leader research for an established Mexican pharmaceutical company.
The pharmaceutical company, a long-time presence in the Mexican market, has contracted the firm for key opinion leader identification, profiling, and engagement strategies in support of a novel prescription medication for the relief of muscle and joint pain. Thought Leader Select will assess the skills and experiences of a host of rheumatologists and orthopedic surgeons throughout Mexico. The pharmaceutical firm will engage the identified medical experts for one-on-one consultations, advisory boards, and speaking engagements, as well as potential clinical studies for new treatment indications for the drug.
In addition to profiles and activity plans for the leading Mexican physicians, Thought Leader Select will also deliver access to its exclusive web-based expert tool for optimizing physician teams for a variety of development activities.
“Our customized services, well-known throughout the United States and Canada, work for companies operating domestically in Mexico as well as multi-nationals doing business throughout Latin America,” stated Dr. Daniel Bagi, head of Latin American business development at Thought Leader Select, from his office in Mexico City. “The launch of this project establishes Thought Leader ... read more »
TAGS: 
advisory boards biopharmaceutical biotechnology Canada clinical studies Daniel Bagi Europe key opinion leader KOL consulting KOL engagement KOL identification KOL profiling KOL strategies Latin America medical conferences medical expert Mexico muscle and joint pain North Carolina orthopedic surgery pain relief pharmaceutical prescription medication Research Triangle rheumatology speakers bureaus thought leader Thought Leader Select treatment indications United States
June 16, 2010 ·
Leave a comment
Daniel Bagi joined Thought Leader Select to steer the company’s business development efforts in Latin America in the spring of 2010. With over two decades working for pharmaceutical and biotechnology companies, Dr. Bagi brings a high level of industry expertise to his consulting work with Thought Leader Select’s clients and prospects.
Daniel earned a Doctor of Medicine degree from the University of Monterrey (Mexico), and he has served the industry in a variety of capacities, including product development, regulatory affairs, licensing, and business development. He directed global clinical development for a suite of anti-cancer drug therapies at Lorus Therapeutics of Markham, Ontario and IGT Pharma of Vancouver, British Columbia.
More recently, Dr. Bagi has served as a senior consultant to EM Diagnostics, a US-based breast cancer diagnostic company, and, since 2005, he has served as a medical consultant to Riso Pharma Tech, a Toronto company dedicated to developing pharmaceuticals for Latin America and the Middle East.
TLS Blog: Good morning, Daniel. Please tell us why you decided to join us at Thought Leader Select.
Daniel Bagi: For me, one of the most important aspects of any professional endeavor is the work environment, which is defined by the attitudes and expertise of your colleagues. Negativity can cause failure. I was first approached by Neil Mellor (principal business development agent for North America), and Neil is ... read more »
TAGS: anti-cancer drug therapies biotechnology breast cancer business development Daniel Bagi Doctor of Medicine EM Diagnostics IGT Pharma investment banking key opinion leaders KOL engagement KOL identification KOL profiling KOLs Latin America liberal arts Lorus Therapeutics medical experts medical school Neil Mellor Paul Meade pharmaceutical pharmaceutical licensing product development regulatory affairs Riso Pharma Tech tennis Thought Leader Select thought leaders University of Monterrey University of Toronto
April 8, 2010 ·
Leave a comment
FOR IMMEDIATE RELEASE
April 8, 2010 (Chapel Hill, NC)—Thought Leader Select, a North Carolina-based firm dedicated to providing solutions for key opinion leader engagement and deployment for the biopharmaceutical industry, announces the expansion of its global business development team.
The research and consulting firm now has business development capabilities to match its track record in global key opinion leader identification research with the additions of Dr. Daniel Bagi and Mr. John Kelly.
Dr. Bagi, who splits his time between Mexico City and Toronto, will serve as Thought Leader Select’s principal agent for Central America, South America, and Spain. Mr. Kelly, of Northampton, UK, will develop Thought Leader Select’s business as its principal agent for Europe and Asia. Bagi and Kelly join Neil Mellor, who joined Thought Leader Select’s team in February of 2009 as its principal agent for North America.
During his 20-year professional career, Daniel Bagi has served the pharmaceutical industry in a variety of capacities, including product development, regulatory affairs, and licensing. Dr. Bagi directed global clinical development for a suite of anti-cancer drug therapies at Lorus Therapeutics of Markham, Ontario and IGT Pharma of Vancouver, British Columbia. More recently, Dr. Bagi has served as a senior consultant to EM Diagnostics, a US-based breast cancer diagnostic company, and, since 2005, he has served as a medical consultant to Riso Pharma Tech, a ... read more »
TAGS: biotechnology Daniel Bagi global business development John Kelly key opinion leaders KOL identification KOL profiling KOL research Kristen Smithwick Neil Mellor pharmaceutical Thought Leader Select
